VX-961 fell at the first hurdle. On Vertex’s fourth-quarter results conference call with investors, Reshma Kewalramani, the company’s chief medical officer, said the phase 1 showed VX-961 lacked the desired pharmacokinetic and tolerability profile.https://www.fiercebiotech.com/biotech/vertex-drops-vx-961-to-continue-search-for-perfect-pain-drug …
0 replies
1 proslijeđeni tweet
2 korisnika označavaju da im se sviđa
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.